Author:
Reimer Jens,Schäfer Ingo,Gallinat Jürgen
Publisher
Springer International Publishing
Reference12 articles.
1. Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCAul ME, Anthenelly R, Salloum I, Galoway G, Garbutt J, Swift R, Gastfriend D, Kallio A, Karhuvaara S. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. Journal of Clinical Psychopharmacology. 2004;24:421–8.
2. Castera P, Stewart E, Großkopf J, Brotons C, Brix Schou M, Zhang D, Steiniger Brach B, Meulien D; on behalf of the PICASO Study Investigators. Nalmefene, given as needed, in the routine treatment of patients with alcohol dependence: an interventional, open-label study in primary care. Eur Addict Res. 2018;24:293–303.
3. European Medicines Agency. Selincro (nalmefene): EU assessment report. 2013. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002583/WC500140326.pdf. Accessed 15 Feb 2021.
4. Gual A, He Y, Torup L, et al. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. European Neuropsychopharmacology. 2013;23:1432–42. https://doi.org/10.1016/j.euroneuro.2013.02.006.
5. Karhuvaara S, Simojoki K, Virta A, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcoholism, Clinical and Experimental Research. 2007;31:1179–87. https://doi.org/10.1111/j.1530-0277.2007.00401.x.